• Prostate Cancer Free Home Page
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • News Feed
  • Get The Study
Prostate Cancer Free
  • Treatments
    • Treatment Options
    • Compare Treatments
    • – Low Risk
    • – Intermediate Risk
    • – High Risk
    • Side Effects
    • Successful Treatments
    • Get The Study & Booklet
  • Prostate Cancer
    • Prostate Cancer
    • Risk Factors
    • Symptoms
    • The Prostate
    • Tests and Diagnosis
    • PSA
    • Gleason Score
    • Stages
    • Risk Groups
  • Patients
    • Top Ten Steps Prostate Cancer
    • Get the Study & Booklet
    • Patient Worksheet
    • Diet & Lifestyle
    • Glossary & Terms
    • Prostate Cancer News
    • Videos
  • The Foundation
    • About Us
      • Terms of Use
      • Privacy Policy
    • Get the Study & Booklet
    • Study Group
    • Internship Opportunities
    • Sponsors & Donors
    • Donate
      • Donate while Shopping at Amazon
  • Get The Study
Select Page

PCa Commentary #160 – Gene Mutations in the BRCA Family and PARP Inhibition Therapy

by Dr. Ed Weber | Jan 6, 2022 | PCa Commentary

PARP [poly (ADP-ribose) polymerase] is a nuclear RNA enzyme essential for repair of single strand DNA damage. It is the default program that repairs damaged DNA that remained unrepaired because of deleterious mutations in the BRCA family of genes, a cell’s first...

PCa Commentary #159 – GENE EXPRESSION PROFILING: Application of Genomics to Therapy Selection for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

by Dr. Ed Weber | Nov 30, 2021 | PCa Commentary

mHSPC: Genomic basis for choice of therapy for men diagnosed with metastatic cancer prior to initial treatment.  Decisions regarding therapy for men with mHSPC will become an increasingly relevant issue as the use of the 68Ga-PSMA-PET/CT and the newly approved...

PCa Commentary #158 – Therapy of the Primary Tumor in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): To Treat or Not to Treat. That is the Question.

by Dr. Ed Weber | Oct 23, 2021 | PCa Commentary

The previous PCa Commentary (Vol. 157) pca-commentary-157-metastatic-hormone-sensitive-prostate cancer/ [control+click link to follow or visit https://prostatecancerfree.org/prostate-cancer-news] addressed the evolution of systemic therapy regimens in de-novo mHSPC...

PCa Commentary #157 – Metastatic Hormone Sensitive Prostate Cancer (mHSPC): Increasing in incidence; Treatment Options Evolving

by Dr. Ed Weber | Sep 29, 2021 | PCa Commentary

Metastatic Hormone Sensitive Prostate Cancer refers to cancers which are found to have metastasized at diagnosis prior to primary treatment and therefore have not been exposed to testosterone deprivation. The incidence of this stage of cancer at diagnosis increased...

PCa Commentary #156 – PYLARIFY — A New PET Imaging Agent for Staging Primary Prostate Cancer and Recurrence

by Dr. Ed Weber | Aug 25, 2021 | PCa Commentary

“Pylarify” is a recently FDA approved tracer for imaging the prostate specific membrane antigen (PSMA) displayed on ~95% of prostate cancer cells. This urea-based radiotracer combines the small molecule DCFPyL, a PSMA targeting agent, with the positron-emitting...
« Older Entries
Next Entries »
Prostate Cancer Free Foundation
Prostate Cancer Free Foundation 10016 Edmonds Way Ste C #153 Edmonds, WA 98020, USA [email protected]

Prostate Cancer Treatments

  • Treatment Options
  • Comparing Treatments
    • Low
    • Intermediate
    • High
  • Side Effects
  • Successful Treatments
  • Get the Study & Booklet

Prostate Cancer

  • Prostate Cancer
  • Risk Factors
  • Symptoms
  • The Prostate
  • Tests and Diagnosis
  • PSA
  • Gleason Score
  • Stages
  • Risk Groups

Patients

  • Top Ten Steps Prostate Cancer
  • Get The Study & Booklet
  • Patient Worksheet
  • Diet & Lifestyle
  • Glossary & Terms
  • Commentary & News
  • Videos
Copyright 2021 Prostate Cancer Free Foundation | WordPress Speed Optimization Service for ProstateCancerFree.org provided by WpFASTER